{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-037060","form_type":"8-K","ticker":"ANGO","cik":"0001275187","company_name":"ANGIODYNAMICS INC","filed_at":"2025-10-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.013290+00:00","generated_at":"2026-05-17T04:54:18.243815+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"AngioDynamics Q1 FY2026: Med Tech sales up 26.1%; raises full-year guidance","bullets":["Net sales $75.7M (+12.2% YoY pro forma); GAAP loss $0.26/sh, adj loss $0.10/sh.","Med Tech segment $35.3M (+26.1%): Auryon +20.1%, thrombectomy +41.2%, NanoKnife +26.7%.","Adjusted EBITDA $2.2M vs ($0.2M) prior year; cash $38.8M, debt-free.","Raised FY2026 guidance: net sales $308-$313M, adj EBITDA $6-$10M, adj EPS ($0.33)-($0.23).","Enrolled first patients in AMBITION BTK and RECOVER-AV trials; PRESERVE study published."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-037060","json":"https://secwatch.observer/filing/0001140361-25-037060.json","markdown":"https://secwatch.observer/filing/0001140361-25-037060.md","text":"https://secwatch.observer/filing/0001140361-25-037060.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1275187/000114036125037060/0001140361-25-037060-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1275187/000114036125037060/ef20056554_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T04:54:18.243815+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}